Axsome Therapeutics, Inc. (AXSM) Position Held by PVG Asset Management Corp
PVG Asset Management Corp held its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,595 shares of the company’s stock at the close of the second quarter. PVG Asset Management Corp owned about 0.09% of Axsome Therapeutics worth $113,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also bought and sold shares of the business. Goldman Sachs Group Inc. lifted its holdings in Axsome Therapeutics by 118.7% during the second quarter. Goldman Sachs Group Inc. now owns 67,618 shares of the company’s stock worth $372,000 after acquiring an additional 36,698 shares in the last quarter. Sphera Funds Management LTD. lifted its holdings in Axsome Therapeutics by 24.9% during the second quarter. Sphera Funds Management LTD. now owns 501,000 shares of the company’s stock worth $2,756,000 after acquiring an additional 100,000 shares in the last quarter. LMR Partners LLP bought a new position in Axsome Therapeutics during the second quarter worth about $206,000. Nexthera Capital LP bought a new position in Axsome Therapeutics during the first quarter worth about $1,560,000. Finally, Royce & Associates LP bought a new position in Axsome Therapeutics during the first quarter worth about $3,436,000. Hedge funds and other institutional investors own 27.12% of the company’s stock.
AXSM has been the topic of several recent analyst reports. Zacks Investment Research lowered Axsome Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, September 22nd. Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $31.00 target price (up from $28.00) on shares of Axsome Therapeutics in a report on Wednesday, July 26th. Aegis reissued a “buy” rating and issued a $20.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, June 20th. Finally, ValuEngine raised Axsome Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, June 21st. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $16.85.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) traded up 3.33% during mid-day trading on Friday, hitting $6.20. The company’s stock had a trading volume of 261,861 shares. The firm has a 50 day moving average of $5.19 and a 200-day moving average of $4.76. Axsome Therapeutics, Inc. has a 52-week low of $3.53 and a 52-week high of $8.68. The firm’s market cap is $146.38 million.
Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Wednesday, August 9th. The company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.01. On average, equities research analysts expect that Axsome Therapeutics, Inc. will post ($1.38) EPS for the current fiscal year.
Axsome Therapeutics Profile
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM).
Receive News & Ratings for Axsome Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.